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ABSTRACT 
Background: A 32-base pair (bp) deletion mutation in the beta- 
chemokine receptor CCR.5 gene has been associated with 
resistance against human immunodeficiency virus type 1 (HIV- 
1) infection and disease. Large-scale studies conducted among 
Caucasians indicate that individuals who are homozygous for 
this deletion mutation (A32/A32) are protected against HIV-I 
infection despite multiple high-risk exposures, whereas CCRS/ 
A32 heterozygotes have a slower progression to acquired 
immunodeficiency syndrome (AIDS). 
Objective: To determine the genotype and allele frequencies of 
the CCR5 gene 32-bp deletion mutation among ethnically 
diverse non-Caucasian populations. 
Methods: DNA, extracted from blood collected between 1980 
and 1997 from 1912 individuals belonging to various ethnic 
groups, including 363 Caucasians, 303 Puerto Rican Hispan- 
ics, 150 Africans, 606 Asians, and 490 Pacific Islanders, were 
analyzed for the CCR.5 gene 32-bp deletion mutation by a poly- 
merase chain reaction (PCR)-based assay, using an oligo- 
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nucleotide primer pair designed to discriminate CCR5 alleles 
without restriction endonuclease analysis. 
Results: The comparative frequency of CCRUA32 hetero- 
zygosity was 61 of 363 (16.8%) in Caucasians, 17 of 303 (5.6%) 
in Puerto Rican Hispanics, 9 of 490 (1.8%) in Pacific Islanders, 
0 of 606 (0%) in Asians, and 0 of 150 (0%) in Africans. 
Conclusions: The data confirm the high frequency of CCR5/A32 
heterozygosity among Caucasians, Intermediate and low-level 
A32 allele frequencies among Puerto Rican Hispanics and 
Hawaiians could be attributed to recent European Caucasian 
gene flow. By contrast, the inability to detect the A32 allele 
among Asians and other Pacific Islander groups suggests that 
other mechanisms are responsible for resistance to HIV-l infec- 
tion in these populations. 
Key Words: chemokine recepfol; human immunodeficiency 
virus, Melanesia, Micronesia, polymerase chain reaction, 
Polynesia, population genetics 
Int J Infect Dis 1999; 3:186-191. 
Presented in part at the 16th Annual Meeting of the American Society 
for Virology, Bozeman, Montana, July 19-23,1997; Fourth International 
Conference on AIDS in Asia and the Pacific, Manila, Philippines, Octo- 
ber 25-29,1997; Fourth Asia-Pacific Congress of Medical Virology Seoul, 
Korea, November 3-5, 1997; and Sixth RCMI International AIDS Sym- 
posium, San Juan, Puerto Rico, November 15-17,199s. 
Supported by U.S. Public Health Service grants G12RR/AI-03061, 
G12RR/AI03050, and P2ORR/AI-11091 from the Research Centers in 
Minority Institutions Program, National Institutes of Health, and fund- 
ing from the Japanese Foundation for AIDS Prevention and the World 
AIDS Foundation Sherimay Ablan was supported in part by a grant 
(R25GM56930) to the Haumana Biomedical Program at the University 
of Hawaii at Manoa. 
Received: January 7,1999; Accepted: April 2,1999. 
Address correspondence to Dr. Yuanan Lu, Retrovirology Research 
Laboratory, Leahi Hospital, 3675 Kilauea Avenue, Honolulu, Hawaii 
96816. E-mail: yluQpbrc.hawaii.edu. 
186 
Population Genetics of CCRS Polymorphism / Lu et al 187 
Entry of human immunodeficiency virus type 1 (HIV-l) 
into target cells requires the binding of the external enve- 
lope glycoprotein gp120 to both the CD4 molecule and 
one of several chemokine receptors, recently discovered 
to function as coreceptors.l-’ T-cell line-tropic HIV-l 
strains utilize the a-chemokine receptor CXCR4,’ whereas 
the B-chemokine receptor 5 (CCR5), which is expressed 
on monocytes/macrophages, ‘I’ cells, and granulocyte pre- 
cursors, is the key cofactor for macrophage-tropic HIV-l 
strainszm6 which predominate during the asymptomatic 
phase of infection. 
A 32-base pair (bp) deletion mutation (A32) within 
the second extracellular loop-encoding region of the 
CCRS gene, which results in a truncated, nonfunctional 
protein, has been associated with relative resistance to 
HIV-l infection and slower progression to acquired 
immunodeficiency syndrome (AIDS).‘-” Specifically, 
A32/A32 homozygotes are protected against acquisition 
of HIV-l by the mucosal route despite high-risk expo- 
sure, whereas disease progression among CCR5/A32 
heterozygotes occurs more slowly. 
Among Caucasians, the genotype frequencies of 
CCR5/A32 heterozygosity and A32/A32 homozygosity 
are 16 to 35% and 1.0 to 3.6%, respectively.7-9z11 Limited 
information is available on the A32 allele frequency 
among non-Caucasian populations.7,9~12-15 To address this 
issue, the authors developed a polymerase chain reaction 
(FCR)-based assay to determine the genotype and allele 
frequencies of this CCR5 polymorphism in nearly 2000 
blood samples collected from various populations, par- 
ticularly those in Asia and the circum-Pacific region. 
MATERIALS AND METHODS 
Study Population 
Blood samples, collected from 1980 to 1997, from 1912 
individuals (1077 HIV-l-infected and 835 uninfected) 
belonging to various ethnic groups were studied: 187 
HIV-1seropositive (48 male and 139 female) and 176 HIV- 
1-seronegative (2 male and 174 female) Caucasians from 
Hawaii; 303 HIV-l-infected Puerto Rican Hispanics; 150 
Africans from Uganda; 606 Asians (279 Vietnamese, 128 
Chinese, 109 Japanese, 42 Indian, 39 Filipino, 9 Korean); 
and 490 Pacific Islanders (253 Polynesians/part-Polyne- 
sians from Hawaii, 216 Melanesians from New Britain, 
and 21 Micronesians from Guam) with or without HIV-l 
infection. Samples were collected in conjunction with 
participation in clinical trials or other studies, as in the 
HIV-l sentinel surveillance program in Vietnam and the 
longitudinal registry for cervical and ovarian cancer 
among women in Hawaii. Demographic data, retrieved 
by coded identifiers, were provided by the respective 
study coordinators. 
Genomic DNA Extraction 
Extraction of genomic DNA from peripheral blood 
mononuclear cells (PBMC), huffy coat samples, or whole 
blood blotted onto filter paper was performed in a 
biosafety laminar-flow cabinet. For the former, PBMC pel- 
lets were resuspended in 50 to 250 yL of cell lysis buffer 
containing 1 X PCR buffer, 2.5 m M  MgCl,, 0.5% NP-40, 
0.5% Tween-20, and 120 pg/mL proteinase K. Mixtures 
were then incubated at 56”~ for 60 minutes, heated at 
100°C for 10 minutes, and stored at 4°C for later use. 
DNA extraction from buffy coat samples was accom- 
plished using a commercially available kit (Promega, Madi- 
son, WI), and extraction from filter paper-blotted blood 
samples, collected from HIV-l-infected individuals in the 
People’s Republic of China and Vietnam, was performed 
according to a previously reported technique.16 Briefly, fil- 
ter paper-blotted blood samples were minced with sterile 
scissors and transferred to a 1.5 mL Eppendo@centrifuge 
tube (Brinkmann Instruments Inc., Wesbury, NY) con- 
taining 300 p,L of 100 m M  NaCl, 10 m M  Tris-HCl (pH 
8.0) 75 kg proteinase K, 0.5% sodium dodecyl sulfate, and 
1 m M  ethylenediaminetetraacetic acid. Following incuba- 
tion with occasional gentle inversion at 56’C for 1.5 hour, 
genomic DNA was isolated using the phenol-chloroform 
method with ethanol precipitation. 
CCR5 Genotyping by PCR 
A targeted region of the CCR5 gene flanking the 32-bp 
deletion was amplified by PCR, using an oligonucleotide 
primer pair designed to discriminate between CCR5 alle- 
les without restriction endonuclease digestion: forward, 
5’-GTCTCTCCCAGGAATCATCTTTACCAGATCTC-3’; 
reverse, 5’-‘ITAGGATICCCGAGTAGCAGATGACCATGACA- 
3’. Each PCR was conducted in a final volume of 50 FL 
containing 0.2 to 0.5 i.i,g template DNA, 1 X PCR buffer, 
200 PM each dN= 1 mM MgCl,, 1.25 U Themus aquati- 
cus DNA polymerase (Perkin-Elmer Corporation, Norwalk, 
CT), and 50 nM each primer. Thermocycling conditions 
consisted of 45 cycles with an initial denaturation at 94’C 
for 5 minutes, followed by denaturation at 94°C for 1 
minute, annealing at 60”~ for 1 minute, and extension at 
72°C for 1 minute. The mutated and unmutated alleles 
appeared as 147-bp and 179-bp amplicons, respectively, 
which were easily distinguishable by ethidium bromide- 
stained gel electrophoresis using 3% NuSieve agarose 
(FMC BioProducts, Rockland, ME). 
To minimize sample carryover, all specimens and 
reagents were handled in a BSL-2 cabinet or UV-mounted 
PCR Workstation (C.B.S. Scientific Co., Del Mar, CA). 
Reagents were dispensed using aerosol-resistant pipette 
tips. Pre-PCR, thermocycling and post-PCR manipulations 
were performed in physically separated cubicles. Addi- 
tionally, two negative controls were used in each PCR run. 
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Validation of CCR5 Genotyping Assay Beverly, MA), incubated for at least 2 hours at 37°C for 
PstI and at 50°C for ApoI. Since the single recognition 
To verify that the 147-bp amplified segment was trun- site of ApoI was within the 32-bp deletion, the presence 
cated because of the 32-bp deletion, randomly selected of the deletion mutation resulted in ApoI resistance and 
PCR amplicons were analyzed by restriction endo- P&I sensitivity. 
nuclease digestion, using two enzymes, ApoI and P&I, To further confirm the specifkity of the PCR-based 
which made single cuts within and upstream of the 32- CCRS assay, representative PCR products were cloned 
bp deletion, respectively (Figure 1, A and B). Each diges- using the TA cloning kit (Invitrogen, San Diego, CA), and 
tion was performed in a 3O+L volume containing the clones were sequenced in both directions on an auto- 
appropriate digestion buffer, 10 PL PCR amplicon, and mated sequencer (model 373A, Applied Biosystems Inc., 
5 units of either ApoI or PstI (New England Biolabs, Inc., Foster City, CA) using the same oligonucleotides 
Figure 1. PCR amplification and restriction endonuclease analysis of CCR5 gene. A, Schematic representation (top) and electrophoretic analy- 
sis (bottom) of cleavage products of the CCRS gene by Apol (cleavage site indicated by closed arrow). Amplified fragments (CCRUCCRS: lanes 
1 and 5; CCRUA32: lanes 2 and 6; A32/A32: lanes 3 and 7) were size fractionated on 3% NuSieve agarose gel before (lanes l-3) and after 
(lanes 5-7) Apol digestion. Lanes 4 and 8 are 50.bp DNA ladders. 6, Schematic representation (top) and agarose gel (bottom) showing the cleav- 
age products of CCR5 gene before and after fstl digestion. Lanes 1 and 2 represent uncut CCRSKCR5 and CCR5/A32, and lanes 4 to 6 are 
digested CCRUA32, CCRS/CCR5, and A32lA32. Lane 3 is the 50-bp DNA ladder. C, 3% NuSieve agarose gel showing wild-type CCRUCCRS 
genotype (lanes 1-l 5) amplified from HIV-1 -negative Melanesians from New Britain. Lanes 16 and 17 are the CCR5/A32 and CCRWCCR5 con- 
trols, respectively. D, PCR amplification of the CCR5/A32 heterozygous genotype in Puerto Rican Hispanics (lanes 1-5) and Caucasians (lanes 
9-15). Lanes 6 and 16 are the 50.bp DNA ladder, and lane 7 is the CCR5/CCR5 control. 
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employed in PCR. Four randomly selected samples from 
each ethnic group were sequenced. Computer-assisted 
sequence analysis was facilitated by DNASTAR (Lasergene 
Biocomputing Software, Madison, WI). 
RESULTS 
To facilitate rapid genetic screening for the A32 allele in 
various ethnic populations, a PCR-based assay was estab- 
lished using an oligonucleotide primer pair designed to 
identify CCR5 genotypes without restriction enzyme 
analysis. Two PCR products, 179 bp and 147 bp in length, 
representing the CCR5 wild-type and A32 mutated alle- 
les, respectively, were easily discriminated by agarose gel 
electrophoresis (see Figure 1). Analyses of the two frag- 
ments by restriction endonuclease digestion and by 
cloning and DNA sequencing verified the 32-bp deletion 
within the shorter amplified product. Specifically, the 147- 
bp product was resistant to ApoI digestion, but sensitive 
to PstI (see Figure 1 ,A and B), and DNA sequencing indi- 
cated that bases 580 to 611 of the CCR5 coding region 
were missing in the 147-bp amplicon (d&a not shown). 
Among Caucasians, the overall frequency of the het- 
erozygous genotype (CCR5/A32) was 16.8% (61/363), 
with a A32 allele frequency of 9.2% (67/726). No differ- 
ence was found in the CCR5/A32 genotype frequency 
between HIV-l-infected (32/187 [ 17.1%]) and HIV-l-un- 
infected (29/176 [16.5%]) Caucasians (Table 1). By con- 
trast, the frequency of the homozygous genotype 
(A32/A32) was 1.7% (3/176) among HIV-l-uninfected 
Caucasians and nil (O/187) among HIV-l-infected Cau- 
casians (see Table 1). 
Four Caucasians who possessed the heterozygous 
genotype (CCR5/A32) were long-term survivors (infected 
for 11 to 13 y), and 13 other individuals (10 Caucasians, 
1 Hispanic, 1 Japanese, and 1 Pacific Islander) infected 
with HIV-l for 13 to 17 years were neither heterozygous 
nor homozygous for the 32-bp deletion mutation. Some 
of these 13 individuals had relatively high CD4 counts 
(>500 cells/mm3) and low plasma viral loads (<lo00 
copies/ml). 
Analysis of the HIV-l-infected Puerto Rican Hispan- 
ics indicated a CCR5/A32 genotype frequency of 5.6% 
(17/303) (see Table 1) and a A32 allele frequency of 2.8% 
(17/606). By contrast, none of 150 Africans from Uganda 
possessed the A32 allele. Also, irrespective of their HIV- 
l-infection status, all of the 606 Asians were homozygous 
for the wild-type or unmutated allele (CCR5KCR5). Sim- 
ilarly, among individuals of Polynesian, Micronesian, and 
Melanesian descent with no known European Caucasian 
admixture, the A32 allele was not found (see Table 1). A 
A32 allele frequency of 1.8% (9/506) and a CCR5/A32 
genotype frequency of 3.6% (9/253) was found among 
Hawaiians, but all nine CCR5/A32 heterozygous Hawai- 
ians had Caucasian parents or grandparents. 
DISCUSSION 
The discovery of a 32-bp deletion mutation in the CCR5 
gene marks a significant step toward understanding the 
critical relation between chemokine receptors and HIV-l 
entry and subsequent disease progression. Genotypic 
analysis of this 32-bp deletion mutation among individu- 
als of European Caucasian descent indicates that approx- 
imately 1 to 3% carry two defective alleles and 15 to 30% 
are heterozygous. 7-9,11 Since polymorphisms of chemokine 
receptor genes appear to result in differential resistance 
and susceptibility to HIV-l disease progression, under- 
standing the allele frequencies of the CCR5 gene 32-bp 
deletion mutation in various ethnic populations may pro- 
vide insights into the evolution of the defective allele, 
and in designing effective chemotherapeutic strategies 
directed against modulating the HIV-l-CCR5 interaction. 
Using a rapid PCR-based assay, nearly 2000 DNA sam- 
ples from Caucasians, Puerto Rican Hispanics, Africans, 
Asians, and Pacific Islanders were examined for the A32 
Table 1. Genotype Frequency of CCR5 Gene 32-bp Deletion Mutation in Various Ethnic Groups 
HIV- 1 -Infected HIV- 1 -Uninfected 
Ethnic Group Total CCR5KCR5 CCR5/A32 A32/A32 Total CCRS/CCR5 CCR5/A32 
Asian 408 408 (1.000) 0 (0.000) 0 (0.000) 198 198 (1.000) 0 (0.000) 
Chinese 103 103 (1.000) 0 (0.000) 0 (0.000) 25 25 (1.000) 0 (0.000) 
Japanese 20 20 (1.000) 0 (0.000) 0 (0.000) 89 89 (1.000) 0 (0.000) 
Vietnamese 279 279 (1.000) 0 (0.000) 0 (0.000) 0 
Filipino 6 6 (1.000) 0 (0.000) 0 (0.000) 33 33 0 
Indian 
(1.000) (0.000) 
0 42 42 (1.000) 0 (0.000) 
Korean 0 9 9 (1.000) 
Puerto Rican 
0 (0.000) 
303 286 (0.944) 17 (0.056) 0 (0.000) 0 
Caucasian 187 155 (0.829) 32 (0.171) 0 (0.000) 176 144 
African 
(0.818) 29 (0.165) 
150 150 (1.000) 0 (0.000) 0 (0.000) 0 
Pacific Islander 29 28 (0.966) 1 (0.034) 0 (0.000) 461 453 
Polynesian 
(0.983) 8 (0.017) 
28 27 (0.964) 1 (0.036) 0 (0.000) 225 217 8 
Melanesian 
(0.964) (0.036) 
1 1 (1.000) 0 (0.000) 0 (0.000) 215 215 
Micronesian 
(1.000) 0 (0.000) 
0 21 21 (1.000) 0 (0.000) 
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allele. The approximately 17% CCR5/A32 heterozygosity 
rate detected among HIV-l-infected and uninfected Cau- 
casians and the A32/A32 homozygosity rate of 1.7% in 
HIV-1-seronegative Caucasians in this study fell within 
the range reported previously for Caucasian popula- 
tions.7-9z11 Despite the apparent resistance afforded by 
the CCR5 gene 32-bp deletion mutation, protection 
against HIV-1 infection is not absolute, as evidenced by 
reports of HIV-l infection among A32/A32 homozy- 
gates.“-‘” Thus far, however, acquisition of HIV-l infection 
in such individuals has been by the parenteral, rather 
than mucosal route, suggesting utilization of the CXCR4 
coreceptor by dual-tropic strains of HIV-1 among infected 
A32/A32 homozygotes. 
A CCR5/A32 heterozygous genotype frequency of 
6.7% has been reported previously for Hispanics living in 
the United States who trace their heritage to Mexico as 
well as to Central and South America.12 In the present 
study, a similar overall low-level CCR5/A32 heterozygos- 
ity of 5.6% was found among Puerto Ricans. Although 
Puerto Ricans are generally classified as Hispanics, their 
genetic composition is rather more complex and diverse, 
with admixture of Caucasian, Taino (and possibly Caribe) 
Indian, and African traits to varying degrees. In this regard, 
albeit to a lesser extent, the low A32 allele frequency 
among Hawaiians can be accounted for by recent Cau- 
casian gene flow or admixture. 
Not unexpectedly, CCR5/A32 heterozygosity was 
found among several long-term survivors. However, many 
more individuals infected with HIV-1 for more than 13 
years and having relatively high CD4 counts and low 
plasma viral loads did not possess the A32 allele, indi- 
cating that polymorphisms other than the CCR5 gene 
32-bp deletion mutation may account for slower pro- 
gression to AIDS in such individuals. Specifically, a G to 
A nucleotide substitution at position 190 in the CCR2 
gene results in a V to I change at position 64 of the CCR2 
protein (CCR2-64l), and this point mutation appears to be 
operative in delayed progression to AIDS.*‘-** In addition, 
a CCR5 gene mutation at position 303 (M303) from T to 
A has recently been identified to be an accomplice in 
conferring resistance to HIV-l infection.23 The M303 
mutation introduced a premature stop codon in the CCR5 
gene, which results in the loss of the expression of a 
functional coreceptor. On the other hand, individuals with 
overproduction of beta-chemokines appear to resist HIV-1 
infection, even in the absence of such polymorphisms in 
the CCR5 or CCR2 gene.** 
Inability to detect the A32 allele in HIV-l-infected 
and -uninfected Asian populations in the present study is 
consistent with previously published reports based on 
smaller numbers of individuals.7,9x14,1j However, the 
absence of the CCR5 gene 32-bp deletion mutation 
among Asians, as well as in Polynesian, Micronesian, and 
Melanesian populations, does not preclude, in such eth- 
nic groups, the existence of other polymorphisms of 
chemokine receptor genes associated with slower pro- 
gression to AIDS. For example, the extraordinarily high fre- 
quencies of the SDP13’A allele among non-Austronesian 
highlanders of Papua New Guinea and aboriginal popu- 
lations of Australia warrants careful clinical correlation.zs 
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